Discover the World’s Fastest Business Insights
Get real-time alerts on funding rounds, executive hires, acquisitions, and more— plus verified contact details and AI-powered outreach to connect faster.
Sign up now to unlock exclusive data and opportunities.
Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines
Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines
Company Info
Company news
Tue, 07 Jan 2025 13:30:00 GMT
Aro Biotherapeutics Appoints Glenn Crater, MD, as Chief Medical Officer - Business Wire
Mon, 15 Aug 2022 07:00:00 GMT
Pompe Disease mRNA Therapy Receives FDA Orphan Drug Designation - CGTLive™
Tue, 05 Jan 2021 08:00:00 GMT
Aro Biotherapeutics Announces $88 Million Series A Financing to Advance Development of Centyrin-Targeted Genetic Medicines - Business Wire
Wed, 11 May 2022 07:00:00 GMT
Aro Biotherapeutics to Present New Preclinical Data Highlighting the Potential of Centyrin-siRNA Conjugates for the Treatment of Pompe Disease - Business Wire
Tue, 02 Apr 2019 07:00:00 GMT
Aro Biotherapeutics to Present Data on Lead Program, ABX900, at AACR - Business Wire
Never Miss an Opportunity: Your #1 Sales Intelligence Tool
Get lightning-fast updates on funding rounds, executive hires, contract awards, and more—powered by AI-driven insights to help you connect with the right prospects first.